Beauty Health Co Overview
Industry: Household & Personal Products
Sector: Consumer Defensive
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California. The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also co Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Beauty Health Co into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net sales was $72.1M (reported). Net loss was -$2.7M (from $19.7M). Adjusted EBITDA was $17M.
What changed
- Net sales reported to $72.1M.
- Net loss was -$2.7M (from $19.7M).
- Net sales were $72.1 million for the second quarter of 2026, a decrease of (7.8)%, compared to the prior year period ("Q2 2025"), due to lower delivery systems and consumables net sales. The Company placed 770 delivery systems during Q2 2026, compared to 957 during Q2 2025.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
US FDA approves Replimune's skin cancer drug after prior rejections
Headline from Reuters: US FDA approves Replimune's skin cancer drug after prior rejections.
US FDA approves Replimune's skin cancer drug
Headline from Yahoo Finance: US FDA approves Replimune's skin cancer drug.
Nu Skin Enterprises Q2 Earnings Meet Estimates, Revenues Down Y/Y
Headline from Yahoo Finance: Nu Skin Enterprises Q2 Earnings Meet Estimates, Revenues Down Y/Y.
Nu Skin Enterprises (NUS) Matches Q2 Earnings Estimates
Headline from Yahoo Finance: Nu Skin Enterprises (NUS) Matches Q2 Earnings Estimates.
Nu Skin Enterprises, Inc. Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: Nu Skin Enterprises, Inc. Q2 2026 Earnings Call Summary.
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Headline from Barron's: Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.